Prognostic performance of early immune and endothelial activation markers in mild-to-moderate COVID-19 outpatients : a nested case-control study
Alemany, Andrea (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Balanza, Núria (Universitat de Barcelona)
Millat-Martinez, Pere (ISGlobal)
Ouchi, Dan (Fight Infectious Diseases Foundation)
Corbacho-Monné, Marc (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT))
Morales-Indiano, Cristian (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Fernández Rivas, Gema (Clinical Laboratory Metropolitana Nord)
Blanco, Ignacio (Clinical Laboratory Metropolitana Nord)
Mitjà, Oriol (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Aguilar, Ruth (Instituto de Salud Carlos III)
Dobaño, Carlota (Instituto de Salud Carlos III)
Bassat, Quique (Universitat de Barcelona)
Moncunill, Gemma (Universitat de Barcelona)
Baro, Bàrbara (ISGlobal)

Date:	2024
Abstract:	Introduction: Evidence on the association of biomarkers of host response to infection with COVID-19 clinical outcomes has focused mainly on hospitalized patients. We investigated the prognostic performance of 39 immune and endothelial activation markers measured early in the course of disease to predict the development of severe COVID-19 and hospitalization. Methods: We conducted a nested case-control study from a randomized clinical trial evaluating the efficacy of COVID-19 convalescent plasma in outpatients aged 50 years or older presenting with mild-to-moderate COVID-19. We selected participants who were hospitalized within 28 days (cases) and who were not (controls) to compare their biomarker levels in plasma samples collected at enrolment. Results: A total of 42 cases and 42 controls were included in this study. The levels of CRP, IL6, IP10, ferritin, IFNα, IL8, IL1RA, MCP1, and RANTES, determined within 7 days of symptoms onset, showed good individual prognostic performance for COVID-19 associated hospitalization by day 28. The biomarkers CRP, IL6, IP10, IL8, IL1RA, and suPAR showed good individual prognostic performance for severe COVID-19. CRP, IL6 and IP10 had the most robust association with both hospitalization and severe COVID-19, with CRP having the highest discriminatory capacity with hospitalization, and IL6 for severe COVID-19. Discussion: Our study shows good prognostic performance of CRP and IL6 for 28-day hospitalization in patients with mild-to-moderate COVID-19, in the absence of clinical criteria for admission upon enrolment. These findings confirm the value of these biomarkers at early stages of COVID-19 disease in the outpatient setting to support management decisions.
Note:	Altres ajuts: ISGlobal (CEX2023-0001290-S); Marie Sklodowska-Curie Actions COFUND Program (BP3, 801370)
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Language:	Anglès
Document:	Article ; recerca ; Versió publicada
Subject:	Biomarkers ; Host response ; COVID-19 ; SARS-CoV-2 ; Outpatients
Published in:	Frontiers in immunology, Vol. 15 (November 2024) , ISSN 1664-3224

DOI: 10.3389/fimmu.2024.1501872
PMID: 39664394

12 p, 3.8 MB

The record appears in these collections:
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Institut d'Investigació en Ciencies de la Salut Germans Trias i Pujol (IGTP)
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Parc Taulí Research and Innovation Institute (I3PT
Articles > Research articles
Articles > Published articles